Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

A once-daily oral GLP-1 conferred greater reductions in HbA1c and body weight than placebo among adults with type 2 diabetes, ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average<a class="excerpt-read-more" href=" More ...

“GLP-1 receptor agonists are popular due to their dual benefits in improving glycemic control for Type 2 diabetes and promoting significant weight loss,” Vukasinov explained. These medications ...

Iuliia Burmistrova/Getty Images GLP-1 drugs have helped people successfully achieve and maintain weight loss ... received approval for treating type 2 diabetes and/or obesity.

Mounjaro and Ozempic were both developed as type 2 diabetes ... gain back the weight due to increase in appetite. One may need a larger portion of food when they do not take GLP-1 drugs anymore.

Researchers conducted a single-centre retrospective study to examine the efficacy and safety of 12 months of treatment with GLP-1 RAs in patients who had weight regain after bariatric surgery.

GLP-1 drugs have helped people successfully achieve and maintain weight loss; however, losing muscle has been a significant concern. New research suggests that weight loss treatments using GLP-1 ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well ...